

Diaverum launches *kidney.com* in France, bringing AI-powered education to the global fight against Chronic Kidney Disease

- Co-developed with M42, a global health leader powered by artificial intelligence (AI), technology, and genomics, *kidney.com* combines the company's three decades of clinical expertise with M42's advanced artificial intelligence capabilities to help patients, care partners and healthcare professionals better understand both chronic and acute kidney conditions
- *kidney.com* signals a broader shift in generative, natural-language AI for healthcare, from general-purpose models to specialized, condition-focused systems capable of understanding medical nuance, enhancing patient engagement and promoting awareness
- Chronic kidney disease affects almost 10% of the general population in France.¹

Paris, France – 19 May 2026. As chronic kidney disease (CKD) becomes one of the fastest-growing global health challenges, placing increasing strain on patients, communities and healthcare systems, Swedish-born global renal care provider Diaverum, part of M42, a global health leader powered by AI, technology and genomics, today unveiled *kidney.com*, a new AI-powered health assistant.

Designed to make trusted, personalized kidney health education more accessible for people, the platform launches today in France, UAE, Germany, Portugal and the UK, with additional markets to follow.

With up to 90% of people unaware they have chronic kidney disease until it is significantly advanced, and many lacking the knowledge and resources necessary to slow its progression, *kidney.com* provides accessible, interactive and personalized education at **no cost**.

With a **conversational AI interface** trained on trusted clinical sources, the platform offers **evidence-based** content on chronic and acute kidney conditions and **tailored learning experiences** that adapt to each user's needs. *kidney.com* aims to raise awareness to help tackle the growing condition. Studies show that patients with low health literacy are more likely to be hospitalized and to use emergency services,² highlighting the direct impact of education on improving health outcomes, controlling costs and reducing inequalities in access to care.

Additional features include **voice control**, product label interpretation via **file upload**, and **multilingual support**, with English, Arabic, French, German and Portuguese interfaces live, and additional languages coming soon.

Rafael Romanini, Chief Executive Officer, Diaverum, said: "At Diaverum, combining science with compassion for meaningful progress in renal care is at the core of our DNA. With *kidney.com*, we're extending that philosophy into the digital world, using AI-powered education to make kidney health

¹ [Prevalence of chronic kidney disease in France: methodological considerations and pitfalls with the use of Health claims databases](#)

² Nancy D., et al. [Low Health Literacy and Health Outcomes: An Updated Systematic Review](#). Ann Intern Med.2011;155:97-107. [Epub 19 July 2011]. doi:[10.7326/0003-4819-155-2-201107190-00005](#)

knowledge accessible, relevant and actionable for everyone, anywhere, 24/7. This initiative reflects our broader commitment to helping people live fulfilling lives, while supporting the sustainability of healthcare systems through education, prevention and innovation.”

CKD is also among the costliest chronic diseases for healthcare systems: in Europe alone, annual costs are estimated at **€140 billion**³.

In France, chronic kidney disease affects 6 million people nationwide; almost 10% of the general population.¹ Despite its prevalence, the condition often remains undiagnosed until advanced stages, highlighting the urgent need for greater awareness, early detection and patient education.

Dr Paul Stroumza, Medical Director for France at Diaverum, says: “Today, too many patients only discover their disease at a late stage. Yet we know that with earlier diagnosis, we can significantly slow its progression. The real challenge is to bring kidney disease out of the blind spot where it still remains.”

Dimitris Moulavasilis, Group Chief Executive Officer, M42, said: “At M42, we are reimagining how technology can empower healthier lives. *kidney.com* harnesses the power of advanced, natural-language AI to confront the one of the world’s fastest-growing lifestyle-related conditions. By combining trusted clinical expertise with intelligent technology, *kidney.com* helps patients, caregivers and entire communities make informed health decisions. This is a prime example of how responsible AI can make care smarter, empowering people to better manage, and, where possible, slow the progression of chronic kidney disease.”

As healthcare moves beyond general-purpose AI, *kidney.com* reflects a broader shift toward specialized, condition-focused systems designed to support real-world care. For quality and relevant health information, *kidney.com* was developed in collaboration with more than 30 nephrologists, physicians and nurses spanning 13 countries and by completing over 14,000 chat interactions during the testing phase to ready the platform for real-world use. Ongoing clinical input is expected as *kidney.com* expands into additional markets. While not a medical device and not designed to diagnose or recommend treatment, *kidney.com* complements professional medical guidance, supports proactive self-management and has been developed in line with applicable privacy and data protection regulations across markets.

Dr. Paul Stroumza, Medical Director for France at Diaverum, added: “Education has always been at the heart of good medicine. When people understand their condition, they’re more engaged and empowered in their care. We have seen time and time again that this improves adherence, reduces complications, and contributes directly to better outcomes. *kidney.com* translates complex, specific renal care knowledge into simple, evidence-based guidance that enhances, not replaces, the vital role of clinicians. It supports healthcare teams by fostering informed conversations and shared decision-making, helping doctors deliver more personalized, preventive and effective care.”

The launch of *kidney.com* underpins Diaverum and M42’s shared commitment to build next-generation healthcare systems powered by AI, data and intelligence. It sets a new standard beyond general AI,

³ [Cost-effectiveness of screening for chronic kidney disease: existing evidence and knowledge gaps - PMC](#)

with clinically specialized, human-centered systems transforming trusted knowledge into everyday understanding to empower individuals and support smarter, data-driven care.

-Ends-

Notes to Editors:

What [kidney.com](https://www.kidney.com) offers

- [Large-language-model AI with a conversational chatbot interface](#)
- Evidence-based content on kidney health and the management of chronic and acute kidney diseases
- AI-powered personalization offering tailored educational materials
- Simple, accessible explanations to help people understand complex medical topics
- Free to access, currently live online in the **France, UAE, Germany, Portugal and the UK**, with additional markets planned by the end of the year. Beta versions are already available for testing in other countries across Europe and Latin America where the company operates
- Additional interactive features for registered users — including voice control and the ability to upload files (e.g. product-label photos) for educational insights
- A platform with an interface and answers available in multiple languages, including French, is available on [kidney.com](https://www.kidney.com)
- A tutorial video is available [here](#)

About Diaverum

Diaverum is a Swedish-born, multinational healthcare organisation that provides life-enhancing renal care to patients with chronic kidney disease, empowering them to live fulfilling lives. Our vision is to transform renal care, delivering and broadening access to the highest quality of kidney care for patients around the world. At the heart of what we do is our standardised care delivery model, continuously evolving digital & AI infrastructure and people caring for patients with competence, passion and inspiration.

As a global leader and the largest independent renal service provider in Europe, we have 14,200 healthcare professionals caring for around 45,000 patients across over 460 clinics in 25 countries globally. We provide renal care personalised to patients' needs and choices, offering a portfolio of treatments ranging from preventive care, haemodialysis, peritoneal dialysis and home care, to the coordination of patients' comorbidities and holiday dialysis.

Founded in 1991 in Malmö, Sweden, Diaverum is part of the M42 group of companies, the global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet.

About M42

M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet. M42 combines its specialized, state-of-the-art facilities with integrated health solutions like genomics and biobanks, and harnesses advanced technologies to deliver precise, preventive and predictive care, to impactfully disrupt traditional healthcare models and positively impact lives globally.



Established in 2023, following the coming together of G42 Healthcare and Mubadala Health, M42 has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned healthcare providers, including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu Dhabi. As well as operating the Emirati Genome Programme, M42 runs Abu Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS), a global tech-enabled healthcare company operating Malaffi.